Drug Pipeline

Ublituximab Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
11
Active Studies
6
Recruiting
4
Phase 3
7
Top Sponsors
3
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-05-29 NCT07211633
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and…		 Trial sites expanded: 42 -> 48 locations
2026-05-16 NCT07211633
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and…		 overall status: "Recruiting" → "Active Not Recruiting"
2026-05-16 NCT07211633
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and…		 date change Primary completion moved earlier: 2026-12-31 -> 2026-10-31
Active Studies by Phase
Phase 4
2
Phase 3
3
Phase 2/3
1
Phase 2
3
Early Phase 1
1
Not specified
1
Active Trials
NCT IDTitleConditionStatus
Phase 4
NCT07225361 Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis Multiple Sclerosis Recruiting
NCT07389590 Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis Multiple Sclerosis Recruiting
Phase 3
NCT05877963 Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of… Relapsing Multiple Sclerosis Recruiting
NCT07211633 A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and… Relapsing Multiple Sclerosis Active, Not Recruiting
NCT04130997 An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis Relapsing Multiple Sclerosis (RMS) Active, Not Recruiting
Phase 2/3
NCT07220252 Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of… Relapsing Multiple Sclerosis Not Yet Recruiting
Phase 2
NCT07103746 Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy Autoimmune Disorders Recruiting
NCT04624633 Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL Chronic Lymphocytic Leukemia Active, Not Recruiting
NCT07503873 A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab… Multiple Sclerosis Not Yet Recruiting
Early Phase 1
NCT06629428 Effects of Ublituximab on Motor Functions in Multiple Sclerosis Multiple Sclerosis (MS) - Relapsing-remitting Recruiting
Not specified
NCT06864936 Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in… Multiple Sclerosis (MS) - Relapsing-remitting Recruiting
Sponsors Running Ublituximab Trials
TG Therapeutics, Inc. (5) Jennifer R. Brown, MD, PhD (1) Georgia State University (1) University of Maryland, Baltimore (1) National Institute of Allergy and Infectious Diseases (NIAID) (1) Northwestern University (1) Johns Hopkins University (1)
Disease Areas
Multiple Sclerosis (9) Leukemia (1) Chronic Lymphocytic Leukemia (CLL) (1)
Get alerts when Ublituximab trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free